Abbott Laboratories (ABT.N)
65.45USD
13 Jul 2012
$0.32 (+0.49%)
$65.13
$65.20
$65.50
$65.15
1,010,735
11,625,128
$66.30
$46.29
ABT.N
About
Overall
| Beta: | 0.30 |
| Market Cap (Mil.): | $102,978.50 |
| Shares Outstanding (Mil.): | 1,573.39 |
| Dividend: | 0.51 |
| Yield (%): | 3.12 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.26 | 41.56 | 44.82 |
| EPS (TTM): | 3.23 | -- | -- |
| ROI: | 11.36 | 9.06 | 9.94 |
| ROE: | 20.39 | 13.25 | 11.61 |
London Metal Exchange CEO expects bid vote approval
* ICE chief says other opportunities for exchanges in OTC
Ablynx says top drug shows benefit over rival
BRUSSELS - Belgian drug developer Ablynx said on Monday its top drug, arthritis treatment ozoralizumab, had shown a benefit over its biggest rival in the $24 billion market for this class of treatment.
UPDATE 2-RLPC: Pricing emerges on Abbott's loans
NEW YORK, June 20 - Details have emerged on the pricing of the $14.5 billion financing package that backs Abbott Laboratories' separation into two publicly traded companies, sources told Thomson Reuters LPC.
Ex-Orioles player Eddie Murray is part of insider trading inquiry
NEW YORK - Hall of Fame baseball player Eddie Murray is one of several former professional athletes under investigation by federal authorities in a U.S. insider trading case stemming from the buyout of a medical device company, people familiar with the three-year-old probe said.
INSIGHT-Ex-Orioles player Eddie Murray is part of insider trading inquiry
* CEO of target, Advanced Medical Optics, also scrutinized
Abbott markets $14.5 billion for spinoff
NEW YORK - Details have emerged on the structure of the $14.5 billion financing package that backs Abbott Laboratories' separation into two publicly traded companies, sources told Thomson Reuters LPC.
UPDATE 1-RLPC: Abbott markets $14.5B for spinoff
NEW YORK, June 20 - Details have emerged on the structure of the $14.5 billion financing package that backs Abbott Laboratories' separation into two publicly traded companies, sources told Thomson Reuters LPC.
RLPC: Abbott markets $14.5B in loans for spinoff
NEW YORK, June 20 - Abbott Laboratories is in market with $14.5 billion in loans, making it the largest loan package year to date in the U.S., sources told Thomson Reuters LPC.
TEXT-S&P; may still cut Abbott Laboratories ratings
Overview -- U.S. diversified pharmaceutical company Abbott Laboratories intends to split off its global proprietary pharmaceutical operations into a separate company, to be named AbbVie, leaving the lower-margin, established pharmaceutical operations with Abbott. -- At this time, neither the exact composition of either business or their financial structure is known, but both will be smaller and less diverse than Abbott is now. -- On Oct. 19, 2011, we placed our 'AA'
India's Piramal Healthcare to buy U.S. firm to boost R&D;
MUMBAI - Indian drugmaker Piramal Healthcare has agreed to buy a U.S.-based healthcare data provider for $635 million to boost research and development, the company said on Wednesday, a month after it acquired the new molecules division of Germany's Bayer's.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $68.61 | +0.90 |
| Pfizer Inc. (PFE.N) | $22.81 | +0.14 |
| GlaxoSmithKline plc (GSK.L) | 1,446.00p | +10.50 |
| Novartis AG (NOVN.VX) | CHF54.65 | +0.10 |
| Eli Lilly & Co. (LLY.N) | $43.26 | +0.42 |
| Merck & Co., Inc. (MRK.N) | $43.47 | +0.56 |
| AstraZeneca plc (AZN.L) | 2,936.50p | +31.00 |
| Sanofi SA (SASY.PA) | €60.74 | +0.41 |
| Amgen, Inc. (AMGN.OQ) | $76.96 | +1.15 |
| Angiotech Pharmaceuticals, Inc. (ANP.TO) | -- | -- |
Earnings vs 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: New Constructs, LLC
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$196.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
